CN117043184A - Nanometer antibody for resisting Human Serum Albumin (HSA) and application thereof - Google Patents
Nanometer antibody for resisting Human Serum Albumin (HSA) and application thereof Download PDFInfo
- Publication number
- CN117043184A CN117043184A CN202280022765.8A CN202280022765A CN117043184A CN 117043184 A CN117043184 A CN 117043184A CN 202280022765 A CN202280022765 A CN 202280022765A CN 117043184 A CN117043184 A CN 117043184A
- Authority
- CN
- China
- Prior art keywords
- antigen
- antibody
- cancer
- binding fragment
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008100 Human Serum Albumin Human genes 0.000 title claims abstract description 77
- 108091006905 Human Serum Albumin Proteins 0.000 title claims abstract description 77
- 108091007433 antigens Proteins 0.000 claims abstract description 149
- 102000036639 antigens Human genes 0.000 claims abstract description 149
- 239000000427 antigen Substances 0.000 claims abstract description 147
- 230000027455 binding Effects 0.000 claims abstract description 145
- 238000009739 binding Methods 0.000 claims abstract description 145
- 239000012634 fragment Substances 0.000 claims abstract description 99
- 102000007562 Serum Albumin Human genes 0.000 claims abstract description 92
- 108010071390 Serum Albumin Proteins 0.000 claims abstract description 92
- 241000282414 Homo sapiens Species 0.000 claims abstract description 55
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 48
- 241000282693 Cercopithecidae Species 0.000 claims abstract description 47
- 210000004027 cell Anatomy 0.000 claims description 75
- 230000035772 mutation Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 34
- 150000007523 nucleic acids Chemical group 0.000 claims description 33
- 229940121354 immunomodulator Drugs 0.000 claims description 29
- 102220645639 ADP-ribosylation factor-like protein 4A_K98Q_mutation Human genes 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 239000012642 immune effector Substances 0.000 claims description 27
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 25
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 25
- 102220585092 Histone H3.Y_A97S_mutation Human genes 0.000 claims description 23
- 241000700159 Rattus Species 0.000 claims description 21
- 101001037140 Homo sapiens Immunoglobulin heavy variable 3-23 Proteins 0.000 claims description 20
- 102100040220 Immunoglobulin heavy variable 3-23 Human genes 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 20
- 102200058948 rs121909541 Human genes 0.000 claims description 20
- 102220082690 rs863224215 Human genes 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 18
- 102220054109 rs72474224 Human genes 0.000 claims description 18
- 102200076470 c.290C>T Human genes 0.000 claims description 16
- 210000004602 germ cell Anatomy 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 102220480355 G-protein coupled receptor 183_R87K_mutation Human genes 0.000 claims description 14
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 102220064391 rs786205838 Human genes 0.000 claims description 14
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 13
- 230000001613 neoplastic effect Effects 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 208000027866 inflammatory disease Diseases 0.000 claims description 12
- 102220237697 rs72650666 Human genes 0.000 claims description 10
- 102220005275 rs33958358 Human genes 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 102220474385 Solute carrier family 13 member 3_S75A_mutation Human genes 0.000 claims description 8
- 102220559219 Voltage-dependent L-type calcium channel subunit alpha-1C_S30R_mutation Human genes 0.000 claims description 8
- 102220370489 c.262G>C Human genes 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 206010038389 Renal cancer Diseases 0.000 claims description 6
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 6
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 206010046851 Uveitis Diseases 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 201000000292 clear cell sarcoma Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 238000010494 dissociation reaction Methods 0.000 claims description 6
- 230000005593 dissociations Effects 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 201000010982 kidney cancer Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010028417 myasthenia gravis Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- -1 LTK Proteins 0.000 claims description 5
- 102220512942 Uncharacterized protein KIAA0087_S85N_mutation Human genes 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102220207584 rs146115797 Human genes 0.000 claims description 5
- 102100025221 CD70 antigen Human genes 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 4
- 230000037431 insertion Effects 0.000 claims description 4
- 230000004068 intracellular signaling Effects 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 239000000700 radioactive tracer Substances 0.000 claims description 4
- 210000003289 regulatory T cell Anatomy 0.000 claims description 4
- 102220075008 rs139397227 Human genes 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 102100027705 Astrotactin-2 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010046080 CD27 Ligand Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 claims description 2
- 102100038027 Diacylglycerol lipase-alpha Human genes 0.000 claims description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 2
- 108010055325 EphB3 Receptor Proteins 0.000 claims description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000936743 Homo sapiens Astrotactin-2 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 claims description 2
- 101000950954 Homo sapiens Diacylglycerol lipase-alpha Proteins 0.000 claims description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims description 2
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101001054649 Homo sapiens Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 claims description 2
- 101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 claims description 2
- 101001039236 Homo sapiens Leucine-rich repeat and fibronectin type-III domain-containing protein 2 Proteins 0.000 claims description 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 2
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 2
- 101001030609 Homo sapiens Mucin-like protein 3 Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101000962438 Homo sapiens Protein MAL2 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000800616 Homo sapiens Teneurin-3 Proteins 0.000 claims description 2
- 101000831862 Homo sapiens Transmembrane protein 45B Proteins 0.000 claims description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 2
- 101000899435 Homo sapiens Uncharacterized protein C1orf159 Proteins 0.000 claims description 2
- 102100022338 Integrin alpha-M Human genes 0.000 claims description 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 2
- 102100027017 Latent-transforming growth factor beta-binding protein 2 Human genes 0.000 claims description 2
- 102100040698 Leucine-rich repeat and fibronectin type-III domain-containing protein 2 Human genes 0.000 claims description 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 2
- 102100025096 Mesothelin Human genes 0.000 claims description 2
- 102100037653 Metalloreductase STEAP3 Human genes 0.000 claims description 2
- 101710147238 Metalloreductase STEAP3 Proteins 0.000 claims description 2
- 102100038572 Mucin-like protein 3 Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100039191 Protein MAL2 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100033191 Teneurin-3 Human genes 0.000 claims description 2
- 102100024181 Transmembrane protein 45B Human genes 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 102100022520 Uncharacterized protein C1orf159 Human genes 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 239000002961 echo contrast media Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 230000005298 paramagnetic effect Effects 0.000 claims description 2
- 239000003504 photosensitizing agent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 244000063299 Bacillus subtilis Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 241001416177 Vicugna pacos Species 0.000 abstract description 28
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 40
- 102000004169 proteins and genes Human genes 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 29
- 229940024606 amino acid Drugs 0.000 description 27
- 239000013598 vector Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 238000002649 immunization Methods 0.000 description 10
- 230000003321 amplification Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 229920002477 rna polymer Polymers 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000562 conjugate Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108010067999 preproalbumin Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229950007269 vobarilizumab Drugs 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-UHFFFAOYSA-N 2-deoxypentose Chemical compound OCC(O)C(O)CC=O ASJSAQIRZKANQN-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000912781 Carcharhinus galapagensis Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101000930477 Mus musculus Albumin Proteins 0.000 description 1
- 102400001111 Nociceptin Human genes 0.000 description 1
- 108090000622 Nociceptin Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 102000007584 Prealbumin Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940069078 citric acid / sodium citrate Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011908 tetrasomy Diseases 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a nano antibody specifically combined with Human Serum Albumin (HSA) and application thereof, and particularly discloses an alpaca capable of combining with Human Serum Albumin (HSA) and a humanized nano antibody or an antigen binding fragment thereof, and has better affinity with human, mouse and monkey serum albumin, and has important significance for treating cancers and autoimmune diseases.
Description
The invention relates to the field of antibodies, in particular to an HSA alpaca nano antibody and a humanized antibody thereof.
Pharmacokinetics is an important parameter in the drug development process. For macromolecular drugs, a longer serum half-life means lower dosing frequency and dosage, and the bioavailability of the drug is correspondingly improved, thereby producing better therapeutic effects. Currently, methods for extending the half-life of drugs are Fc fusion, polyethylene glycol PEG coupling, and Human Serum Albumin (HSA) fusion.
HSA is a novel molecule with a molecular weight of 67kD, constituting two-thirds of the mass of serum proteins, and having many physiological properties. Serum albumin carries many endogenous substances such as inorganic ions, fatty acids, bilirubin, vitamins, hormones and steroids. And is also a carrier for many exogenous drugs. The HSA protein has 17 disulfide bonds inside, so that the whole protein has good stability, the HSA has the advantages of prolonging half-life period, promoting the drug to permeate blood brain barrier and the like, is not easy to permeate kidney glomeruli, has half-life period of 2 weeks in plasma, is widely distributed in vivo and has no immunogenicity, and is a relatively ideal protein drug carrier. However, the HSA fusion protein has limited application range to some extent due to its large molecular weight, low expression level, difficulty in purification, and the like.
Single domain antibodies are a class of antibodies that naturally lack the light chain but only the heavy chain variable region, and have a relative molecular weight of only 15kD, which is only about 1/10 of the molecular weight of a conventional antibody, and thus are also referred to as nanobodies or VHH antibodies. Nanobodies are the smallest unit of antigen binding with complete function that is currently available. Because of its small molecular weight, good stability and flexible chemical properties, it is often used as an ideal form for building bispecific antibodies.
Developing a nano antibody targeting HSA, and constructing a fusion protein by taking the nano antibody as a structural block for prolonging the half life of an active drug, becomes an important drug development strategy, such as a protein drug Vobarilizumab targeting IL6R, wherein the anti-HSA nano antibody is contained as the structural block.
The invention relates to a humanized HSA nano antibody with a brand new sequence, which can specifically identify serum albumin of human, monkey and mouse and has good binding activity.
Disclosure of Invention
The present invention discloses HSA nanobody or antigen binding fragment, multispecific antigen binding molecule, chimeric antigen receptor, immune effector cell, nucleic acid fragment, vector, cell, composition, preparation method, pharmaceutical use, and disease treatment method.
In some embodiments, an isolated nanobody or antigen-binding fragment that specifically binds Human Serum Albumin (HSA) comprises a combination of CDRs of the heavy chain variable region comprising: HCDR1, HCDR2 and HCDR3; the HCDR1, HCDR2 and HCDR3 have any sequence combination selected from the group consisting of:
each of HCDR1, HCDR2 and HCDR3 is encoded according to a current analytical method of KABAT, chothia or IMGT; preferably, the substitution is a conservative amino acid substitution.
In particular, for example, nanobodies or antigen-binding fragments of the invention, wherein:
(1) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.31, 32 and 33;
(2) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.34, 35 and 36;
(3) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.37, 38 and 36;
(4) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.39, 40 and 41;
(5) The HCDR1, HCDR2 and HCDR3 are respectively shown as sequences shown in SEQ ID NO.42, 43 and 44;
(6) The HCDR1, HCDR2 and HCDR3 are respectively shown as sequences shown in SEQ ID NO.45, 46 and 44;
(7) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.47, 48 and 49;
(8) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.50, 51 and 52;
(9) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.53, 54 and 52; or alternatively, the first and second heat exchangers may be,
(10) The HCDR1, HCDR2 and HCDR3 are a sequence combination having 1, 2, 3 or more amino acid insertions, deletions and/or substitutions compared to a sequence combination of (1) - (9) above; substitutions are preferred, more preferably conservative amino acid residue substitutions.
In another specific embodiment, the framework regions of the heavy chain variable regions of the nanobodies or antigen-binding fragments of the invention are derived from human germline heavy chains, wherein:
(1) The framework region sequence is derived from the combined sequence of human germline heavy chains IGHV3-23 x 04 and IGHJ2 x 01; which comprises SEQ ID NO:28, the FR1, FR2, FR3 regions of igfv 3-23 x 04 and SEQ ID NO:29 to igfj 2 x 01;
(2) The framework region sequence is derived from the combined sequence of human germline heavy chains IGHV3-23 x 04 and IGHJ3 x 01; which comprises SEQ ID NO:28, the FR1, FR2, FR3 regions of igfv 3-23 x 04 and SEQ ID NO:30, the FR4 region of IGHJ3 x 01.
In another specific embodiment, the framework regions of the heavy chain variable region of the nanobody or antigen-binding fragment of the invention further comprise one or more mutations according to Kabat numbering selected from the group consisting of:
(1) E1Q, S30N, V F, I70V, S3756A, Q82E, S85N, A97R, K98Q, W109R or L114Q; preferably including S30N, V37F, I70V, A97R, K98Q and W109R; or preferably S30N, V37F, I70V, A97R, K98Q, W109R and E1Q; or preferably comprises S30N, V37F, I70V, A97R, K98Q, W109R and S75A; or preferably S30N, V37F, I70V, A97R, K98Q, W109R and Q82E; or preferably comprises S30N, V37F, I70V, A97R, K98Q, W109R and S85N; or preferably comprises S30N, V37F, I70V, A97R, K98Q, W109R and L114Q;
(2) E1Q, A23V, F V, T28D, S R, S6275A, R87K, A88F, T M, A97V, K98Q, W P or M116Q; preferably including E1Q, F27V, T D, S R, S75A, T91M, A97V, K98Q, W P and M116Q; preferably including F27V, T28D, S30R, S A, T91M, A97V, K3598Q, W111P and M116Q; preferably including F27V, T28D, S R, T91M, A97V, K98Q, W P and M116Q; preferably including F27V, T28D, S30R, R87K, A88F, T91M, A97V, K98Q, W P and M116Q; preferably including E1Q, A23V, F27V, T D, S30R, S A, A97V, K Q and W111P; preferably comprising a23V, F27V, T28D, S R, S30 6275A, A97V, K Q and W111P; preferably including F27V, T28D, S30R, R87K, A F, T91M, A97V, K Q and W111P;
(3) V2L, T28A, S75A, R87K, A88P, A97S, K I or W104S; preferably comprising a97S and K98I; preferably comprising a97S, K I and W104S; preferably comprising V2L, A97S, K I and W104S; preferably including T28A, A97S, K I and W104S; preferably comprising V2L, T28A, A97S, K98I and W104S; preferably, R87K, A88P, A97S, K98I and W104S; preferably comprising V2L, T28A, S A, A97S, K98I and W104S; preferably V2L, T28A, R87K, A88P, A97S, K98I and W104S.
In particular, the nanobody or antigen-binding fragment of the invention further comprises:
(1) The variable region has a sequence shown in SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27;
(2) An amino acid sequence having at least 90% identity, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity, to the sequence shown in (1) above; or alternatively, the first and second heat exchangers may be,
(3) The framework regions of the nanobody or antigen-binding fragment have at least 90% identity, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity, to the framework regions of the amino acid sequences shown in SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27.
In a preferred embodiment, the nanobody or antigen-binding fragment of the invention binds to human serum albumin, monkey serum albumin and/or rat serum albumin; alternatively, the antibody or antigen binding fragment binds to human serum albumin, monkey serum albumin, and/or rat serum albumin with a dissociation constant (KD) of less than 1.00E-8M, 2.00E-8M, 3.00E-8M, 1.00E-9M, 2.00E-09M, 3.00E-9M, 4.00E-09M, 5.00E-09M, 6.00E-09M, 7.00E-09M, 8.00E-09M, 9.00E-09M, 1.00E-10M, 2.00E-10M, 3.00E-10M, 4.00E-10M, 5.00E-10M, 6.00E-10M, 7.00E-10M, 8.00E-10M, 9.00E-10M, 1.00E-11M, 2.00E-11M, 3.00E-11M, 4.00E-11M, 1.00E-10M, 2.00E-11M, 3.00E-12.00E-12M, 12.00E-12M, 3.00E-12.00E-12M;
alternatively, the nanobody or antigen-binding fragment binds to mouse serum albumin or does not bind.
In a preferred embodiment, the antibody or antigen binding fragment of the invention comprises the sequence of the constant region of any one of antibodies IgG1, igG2, igG3, igG4, igA, igM, igE or IgD; preferably comprising the sequences of the constant regions of antibodies IgG1, igG2, igG3 or IgG 4.
In a preferred embodiment, the antibody or antigen binding fragment of the invention further comprises an antibody constant region sequence in the absence of a CH1 fragment.
In a preferred embodiment, the antibody or antigen-binding fragment of the invention further comprises an antibody constant region sequence having CH2 and CH3 fragments, or the antibody or antigen-binding fragment further comprises an antibody Fc region;
the antibody constant region or antibody Fc region is linked to the antibody or antigen binding fragment with or without a linking peptide;
alternatively, the antibody constant region or antibody Fc region is from a camelid, mouse, rat, rabbit, sheep or human;
alternatively, the antibody constant region or antibody Fc region is from IgG, igA, igM, igD or IgE.
In a preferred embodiment, the antibody or antigen binding fragment thereof of the invention is chimeric or humanized or fully human; preferably, the antibody or antigen binding fragment is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, natural antibodies, engineered antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, full length antibodies, antibody fragments, naked antibodies, conjugated antibodies, humanized antibodies, fully human antibodies, fab ', F (ab') 2, fd, fv, scFv, diabodies (diabodies), or single domain antibodies.
In a preferred embodiment, the antibody or antigen binding fragment thereof of the invention is further conjugated to a therapeutic agent or tracer; preferably, the therapeutic agent is selected from the group consisting of a radioisotope, a chemotherapeutic agent or an immunomodulator, and the tracer is selected from the group consisting of a radiocontrast agent, a paramagnetic ion, a metal, a fluorescent label, a chemiluminescent label, an ultrasound contrast agent or a photosensitizer.
In a preferred embodiment, the invention also provides a multispecific antigen-binding molecule; preferably, the multispecific antigen-binding molecule comprises a first antigen-binding moiety comprising an antibody or antigen-binding fragment of any one of the above, and a second antigen-binding moiety that specifically binds to an antigen other than HSA or to an HSA epitope different from the first antigen-binding moiety;
preferably, the additional antigen is selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CDW52, CD69, CD70, CD134 (OX 40), ICOS, BCMP7, CD137, CD27L, CDCP1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, MSLN;
Preferably, the multispecific antibody is a bispecific antibody, a trispecific antibody, or a tetraspecific antibody.
In a preferred embodiment, the invention provides a Chimeric Antigen Receptor (CAR); preferably, the chimeric antigen receptor comprises at least an extracellular antigen binding domain comprising the HSA antibody or antigen binding fragment of any of the above, a transmembrane domain, and an intracellular signaling domain.
In a preferred embodiment, the invention provides an immune effector cell; preferably, the immune effector cell comprises the chimeric antigen receptor described above or a nucleic acid fragment comprising the chimeric antigen receptor described above;
preferably, the immune effector cell is selected from T cells, NK cells (natural killer cell), NKT cells (natural killer cell), monocytes, macrophages, dendritic cells or mast cells; the T cells may be selected from inflammatory T cells, cytotoxic T cells, regulatory T cells (tregs) or helper T cells;
preferably, the immune effector cell is an allogeneic immune effector cell or an autoimmune cell.
In a preferred embodiment, the present invention provides an isolated nucleic acid molecule encoding a nanobody, an antigen-binding fragment, or any combination thereof, as described in any of the above, a multispecific antigen-binding molecule, or a chimeric antigen receptor, as described above.
In some embodiments, the invention provides an expression vector comprising the isolated nucleic acid molecule of the invention described above.
In some embodiments, the invention provides a host cell comprising an isolated nucleic acid molecule or expression vector of the invention described above.
In a preferred embodiment, the host cell is a eukaryotic cell or a prokaryotic cell; more preferably, the host cell is derived from mammalian cells, yeast cells, insect cells, E.coli and/or B.subtilis; more preferably, the host cell is selected from the group consisting of an Expi293F cell.
In some embodiments, the invention provides a method of producing an antibody or antigen-binding fragment or multispecific antigen-binding molecule, culturing a host cell of the invention described above under appropriate conditions, and isolating the antibody or antigen-binding fragment or multispecific antigen-binding molecule.
In some embodiments, the invention provides a method of preparing an immune effector cell, introducing a nucleic acid fragment of the CAR described above into the immune effector cell, preferably the method further comprises initiating expression of the CAR described above by the immune effector cell.
In some embodiments, the invention provides a pharmaceutical composition comprising an antibody or antigen binding fragment of the invention described above, a multispecific antigen-binding molecule of the invention described above, a chimeric antigen receptor of the invention described above, an immune effector cell of the invention described above, an isolated nucleic acid molecule of the invention described above, an expression vector of the invention described above, a cell of the invention described above, or a product (e.g., an antibody and antigen binding fragment) made by the method of the invention described above, and a pharmaceutically acceptable carrier.
In a preferred embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent or adjuvant; more preferably, the pharmaceutical composition further comprises an additional anti-tumor agent.
In some embodiments, the invention provides the use of an antibody or antigen binding fragment as described above, a multispecific antigen binding molecule as described above, a chimeric antigen receptor as described above, an immune effector cell as described above, an isolated nucleic acid molecule as described above, an expression vector as described above, a cell as described above, a product (e.g., an antibody and antigen binding fragment) as described above, or a pharmaceutical composition as described above, in the manufacture of a medicament for the prevention and/or treatment of a neoplastic disease or inflammatory disease, preferably melanoma, clear cell sarcoma, head and neck cancer, bladder cancer, breast cancer, colon cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, kidney cancer, prostate cancer, salivary gland cancer, lung cancer, liver cancer, skin cancer, or brain cancer; the inflammatory disease is preferably multiple sclerosis, psoriasis, myasthenia gravis, uveitis, systemic lupus erythematosus, or rheumatoid arthritis.
In some embodiments, the invention provides a method of preventing and/or treating a neoplastic disease or inflammatory disease comprising administering to a patient in need thereof an antibody or antigen binding fragment of the invention described above, a multispecific antigen binding molecule of the invention described above, a chimeric antigen receptor of the invention described above, an immune effector cell of the invention described above, an isolated nucleic acid molecule of the invention described above, an expression vector of the invention described above, a cell of the invention described above, a product made by a method of the invention described above, or a pharmaceutical composition of the invention described above; the neoplastic disease is preferably melanoma, clear cell sarcoma, head and neck cancer, bladder cancer, breast cancer, colon cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, renal cancer, prostate cancer, salivary gland cancer, lung cancer, liver cancer, skin cancer, or brain cancer; the inflammatory disease is preferably multiple sclerosis, psoriasis, myasthenia gravis, uveitis, systemic lupus erythematosus, or rheumatoid arthritis.
In some embodiments, the invention provides an antibody or antigen binding fragment as described above, a multispecific antigen binding molecule as described above, a chimeric antigen receptor as described above, an immune effector cell as described above, an isolated nucleic acid molecule as described above, an expression vector as described above, a cell as described above, a product (e.g., an antibody and antigen binding fragment) as described above, or a pharmaceutical composition as described above for use in preventing and/or treating a neoplastic disease or inflammatory disease; the neoplastic disease is preferably melanoma, clear cell sarcoma, head and neck cancer, bladder cancer, breast cancer, colon cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, renal cancer, prostate cancer, salivary gland cancer, lung cancer, liver cancer, skin cancer, or brain cancer; the inflammatory disease is preferably multiple sclerosis, psoriasis, myasthenia gravis, uveitis, systemic lupus erythematosus, or rheumatoid arthritis.
In some embodiments, the invention provides a kit comprising an antibody or antigen binding fragment of the invention described above, a multispecific antigen-binding molecule of the invention described above, a chimeric antigen receptor of the invention described above, an immune effector cell of the invention described above, an isolated nucleic acid molecule of the invention described above, an expression vector of the invention described above, a cell of the invention described above, or a product (e.g., an antibody and antigen binding fragment) made by a method of the invention described above, or a pharmaceutical composition of the invention described above, and instructions for use.
Definition and description of terms
Unless otherwise indicated, terms used herein have meanings commonly understood by one of ordinary skill in the art. For a term explicitly defined herein, the meaning of that term controls the definition.
As used herein, the term "antibody" (Ab) refers to immunoglobulin molecules that specifically bind to or are immunoreactive with an antigen of interest, including polyclonal, monoclonal, genetically engineered and other modified forms of the antibody (including but not limited to chimeric antibodies, humanized antibodies, fully human antibodies, heteroconjugate antibodies (e.g., bispecific, trispecific and tetraspecific antibodies, diabodies, trisomy and tetrasomy), antibody conjugates, and antigen-binding fragments of the antibody (including, e.g., fab ', F (Ab ') 2, fab, fv, rIgG and scFv fragments). Furthermore, unless otherwise indicated, the term "monoclonal antibody" (mAb) is intended to include intact antibody molecules capable of specifically binding to the target protein as well as incomplete antibody fragments (e.g., fab and F (Ab ') 2 fragments that lack the Fc fragment of the intact antibody (that is cleared more rapidly from the animal cycle), and thus lack Fc-mediated effector functions (effector function) (see Wahl et al, j. Nucl. Med.24:316,1983; the disclosure of which is incorporated herein).
The "antibody" herein may be derived from any animal, including but not limited to humans and non-human animals, which may be selected from primates, mammals, rodents and vertebrates, such as camelids, llamas, primo-ostris, alpacas, sheep, rabbits, mice, rats or chondrilleids (e.g. shark).
The term "monospecific" herein refers to having one or more binding sites, wherein each binding site binds to the same epitope of the same antigen.
The term "multispecific" herein refers to having at least two antigen-binding sites, each of which binds to a different epitope of the same antigen or to a different epitope of a different antigen. Thus, terms such as "bispecific," "trispecific," "tetraspecific," and the like refer to the number of different epitopes to which an antibody/antigen binding molecule can bind.
"full length antibody", "intact antibody" and "whole antibody" are used interchangeably herein to mean that they have a structure substantially similar to the structure of a native antibody.
As used herein, the term "antigen binding fragment" refers to one or more antibody fragments that retain the ability to specifically bind a target antigen. The antigen binding function of an antibody may be performed by a fragment of a full-length antibody. The antibody fragment may be a Fab, F (ab') 2, scFv, SMIP, diabody, triabody, affibody (affibody), nanobody, aptamer, or domain antibody. Examples of binding fragments that encompass the term "antigen-binding fragment" of an antibody include, but are not limited to: (i) Fab fragment, a monovalent fragment consisting of VL, VH, CL and CH1 domains; (ii) A F (ab) 2 fragment, a bivalent fragment comprising two Fab fragments linked at a hinge region by a disulfide bond; (iii) an Fd fragment consisting of VH and CH1 domains; (iv) Fv fragments consisting of the VL and VH domains of the antibody single arm; (V) a dAb comprising VH and VL domains; (vi) dAb fragments consisting of VH domains (Ward et al Nature 341:544-546,1989); (vii) a dAb consisting of a VH or VL domain; (viii) an isolated Complementarity Determining Region (CDR); and (ix) a combination of two or more isolated CDRs, which may optionally be connected by a synthetic linker. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, these two domains can be joined, using recombinant methods, by a linker that enables them to be made into a single protein chain in which the VL and VH regions pair to form a monovalent molecule (known as a single chain Fv (scFv); see, e.g., bird et al, science 242:423-426,1988, and Huston et al, proc. Natl. Acad. Sci. USA 85:5879-5883,1988). These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and these fragments are screened for use in the same manner as whole antibodies. Antigen binding fragments may be produced by recombinant DNA techniques, enzymatic or chemical cleavage of intact immunoglobulins, or in some embodiments by chemical peptide synthesis procedures known in the art.
As used herein, the term "serum albumin" refers to the most abundant blood protein and functions as a carrier protein for steroids, fatty acids and thyroid hormones in the blood and plays a major role in stabilizing extracellular fluid volume. For purposes of nomenclature only and not limitation, an exemplary sequence of human serum albumin is shown in NCBI GenBank accession No. AEE 60908. It is understood that references to "serum albumin" or "albumin" include preproalbumin (preproalbumin) which comprises an N-terminal peptide, a proprotein (proalbumin) and a secreted albumin. Albumin comprises three homologous domains, each of which is the product of two subdomains having a common structural motif. Domains I, II and III can be defined with reference to human serum albumin. For example, domain I comprises amino acids 1 (±1 to 15 amino acids) to 194 (±1 to 15 amino acids) of human serum albumin, domain II comprises amino acids 192 (±1 to 15 amino acids) to 387 (±1 to 15 amino acids) of human serum albumin, and domain III comprises amino acid residues 381 (±1 to 15 amino acids) to 585 (±1 to 15 amino acids) of human serum albumin. The phrase "±1 to 15 amino acids" means that the amino acid residue may deviate from the C-terminus and/or N-terminus of the amino acid position referred to by 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 amino acids. Exemplary domains I, II and III are described by Dockal et al (The Journal of Biological Chemistry,1999, volume 274 (41): 29303-29310) and Kjeldsen et al (Protein Expression andPurification,1998, volume 13: 163-169).
As used herein, the term "bispecific antibody" refers to an antibody, typically a human or humanized antibody, having monoclonal binding specificity for at least two different antigens. In the present invention, one of the binding specificities may be detected against an epitope of HSA and the other may be detected against another epitope of HSA or against any other antigen than HSA, e.g. against a cell surface protein, a receptor subunit, a tissue specific antigen, a virus-derived protein, a virus-encoded envelope protein, a bacteria-derived protein or a bacteria-surface protein, etc.
As used herein, the term "chimeric" antibody refers to an antibody having a variable sequence derived from an immunoglobulin of one origin organism (e.g., rat or mouse) and constant regions derived from an immunoglobulin of a different organism (e.g., human). Methods for producing chimeric antibodies are known in the art. See, e.g., morrison,1985, science 229 (4719): 1202-7; oi et al, 1986,Bio Techniques 4:214-221; gilles et al 1985J Immunol Methods 125:191-202; the above is incorporated by reference herein.
As used herein, the term "nanobody" refers to a natural heavy chain antibody lacking a light chain, whose variable region is cloned to give a single domain antibody consisting of only the heavy chain variable region, also known as VHH (Variable domain of heavy chain of heavy chain antibody), which is the smallest functional antigen-binding fragment. For further description of VHH and nanobodies, reference is made to the review article by Muyldermans (2001,Reviews in Molecular Biotechnology 74:277-302), and to the following patent applications mentioned as general background: WO 94/04678, WO 95/04079 and WO 96/34103 at the university of Brussell freedom; WO 94/25591, WO 99/37681, WO 00/40968, WO 00/43507, WO 00/65057, WO 01/40310, WO 01/44301, EP 1134231 and WO 02/48193 in the form of Co-pending U.S. Pat. No.; WO 97/49505, WO 01/21817, WO 03/035694, WO 03/054016 and WO 03/055527 of Vlaams Instituut voor Biotechnologie (VIB); WO03/050531 to Alganomics N.V. and Ablynx N.V.; WO 01/90190 to Canadian national research council; WO 03/025020 (=ep 1433793) of Institute of Antibodies; and Ablynx N.V. WO 04/041687, WO 04/041682, WO 04/041685, WO 04/041683, WO 04/062551, WO 05/044858, WO 06/40153, WO 06/079372, WO 06/122786, WO 06/122787 and WO 06/122825, and Ablynx N.V. further published patent applications. Reference is also made to the further prior art mentioned in these applications, in particular to the list of references mentioned on pages 41-43 of international application WO 06/040153, which list and references are incorporated herein by reference. Nanobodies (particularly VHH sequences and partially humanized nanobodies) can be characterized, inter alia, by the presence of one or more "feature residues" in one or more framework sequences, as described in these references. Further descriptions of nanobodies, including humanization and/or camelization of nanobodies, as well as other modifications, parts or fragments, derivatives or "nanobody fusions", multivalent constructs (including some non-limiting examples of linker sequences) and different modifications that increase half-life of nanobodies and their formulations, can be found, for example, in WO 08/101985 and WO 08/142164. For further general description of nanobodies, reference is made to the prior art cited herein, for example as described in WO08/020079 (page 16).
As used herein, the term "complementarity determining region" (CDR) refers to a hypervariable region found in both the light and heavy chain variable domains. The more conserved portions of the variable domains are called the Framework Regions (FR). As understood in the art, the amino acid positions representing the hypervariable regions of an antibody may vary depending on the context and various definitions known in the art. Some positions within the variable domain may be considered heterozygous hypervariable positions, as these positions may be considered to be within a hypervariable region under one set of criteria (e.g. IMGT or KABAT) and outside a hypervariable region under a different set of criteria (e.g. KABAT or IMGT). One or more of these locations may also be found in the extended hypervariable region. The invention includes antibodies comprising modifications in the positions of these heterozygous hypermutations. The variable domains of the natural heavy and light chains each comprise four framework regions, principally in a lamellar configuration, which are linked by three CDRs (CDR 1, CDR2 and CDR 3) that form loops connecting the lamellar structure and in some cases form part of the lamellar structure. The CDRs in each chain are held closely together by the FR regions in sequence FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 and with CDRs from other antibody chains contribute to the formation of the antigen binding site of the antibody (see Kabat et al Sequences of Protein sofImmunological Interest, national Institute of Health, bethesda, md.1987; incorporated herein by reference).
The term "Kabat numbering system" herein generally refers to the immunoglobulin alignment and numbering system proposed by Elvin a.kabat (see, e.g., kabat et al, sequences of Proteins of Immunological Interest,5th Ed.Public Health Service,National Institutes of Health,Bethesda,Md, 1991).
The term "Chothia numbering system" herein generally refers to the immunoglobulin numbering system proposed by Chothia et al, which is a classical rule for identifying the boundaries of CDR regions based on the position of structural loop regions (see, e.g., chothia & Lesk (1987) J.mol. Biol.196:901-917; chothia et al (1989) Nature 342:878-883).
The term "IMGT numbering system" herein generally refers to the immunoglobulin numbering system proposed by Chothia et al, which is a classical rule for identifying the boundaries of CDR regions based on the position of structural loop regions (see, e.g., chothia & Lesk (1987) J.mol. Biol.196:901-917; chothia et al (1989) Nature 342:878-883).
As used herein, the term "monoclonal antibody" refers to an antibody derived from a single clone (including any eukaryotic, prokaryotic, or phage clone), and is not limited to the method of production of the antibody.
As used herein, the term "VH" refers to the variable region of an immunoglobulin heavy chain of an antibody (including the heavy chain of Fv, scFv, or Fab). The term "VL" refers to the variable region of an immunoglobulin light chain (including the light chain of Fv, scFv, dsFv or Fab).
The term "heavy chain constant region" herein refers to the carboxy-terminal portion of an antibody heavy chain that does not directly participate in binding of the antibody to an antigen, but exhibits effector functions, such as interactions with Fc receptors, that have more conserved amino acid sequences relative to the variable domains of the antibody. The "heavy chain constant region" comprises at least one of: a CH1 domain, a hinge region, a CH2 domain, a CH3 domain, or a variant or fragment thereof. "heavy chain constant regions" include "full length heavy chain constant regions" having a structure substantially similar to that of a natural antibody constant region and "heavy chain constant region fragments" including only a portion of the "full length heavy chain constant region. Illustratively, a typical "full length antibody heavy chain constant region" consists of a CH1 domain-hinge region-CH 2 domain-CH 3 domain; when the antibody is IgE, it further comprises a CH4 domain; when an antibody is a heavy chain antibody, then it does not include a CH1 domain. Exemplary, a typical "heavy chain constant region fragment" may be selected from a CH1, fc, or CH3 domain.
The term "light chain constant region" herein refers to the carboxy-terminal portion of an antibody light chain, which is not directly involved in binding of an antibody to an antigen, and which may be selected from a constant kappa domain or a constant lambda domain.
The term "Fc" herein refers to the carboxy-terminal portion of an antibody that is formed by the proteolytic hydrolysis of papain in to an intact antibody, typically comprising the CH3 and CH2 domains of the antibody. The Fc region includes, for example, native sequence Fc regions, recombinant Fc regions, and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain may vary slightly, the Fc region of a human IgG heavy chain is generally defined as extending from amino acid residue position Cys226 or from Pro230 to its carboxy terminus. The C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinant engineering of the nucleic acid encoding the heavy chain of the antibody, and thus the Fc region may or may not include Lys447.
The term "humanized antibody" as used herein refers to a genetically engineered non-human antibody whose amino acid sequence is modified to increase homology with the sequence of a human antibody. Typically, all or part of the CDR regions of a humanized antibody are derived from a non-human antibody (donor antibody) and all or part of the non-CDR regions (e.g., variable region FR and/or constant regions) are derived from a human immunoglobulin (acceptor antibody). Humanized antibodies generally retain or partially retain the desired properties of the donor antibody, including, but not limited to, antigen specificity, affinity, reactivity, ability to enhance immune cell activity, ability to enhance immune responses, and the like.
The term "fully human antibody" herein refers to an antibody having variable regions in which both the FR and CDR are derived from human germline immunoglobulin sequences. Furthermore, if the antibody comprises constant regions, the constant regions are also derived from human germline immunoglobulin sequences. Fully human antibodies herein may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, herein "fully human antibody" is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (e.g., mouse) have been grafted onto human framework sequences.
The term "naked antibody" herein refers to an antibody that is not linked, fused or conjugated to another agent or molecule (e.g., a label or drug), peptide or polypeptide. In particular embodiments, the naked antibody expressed by a mammalian host cell may be glycosylated by the glycosylation machinery (e.g., glycosylase) of the host cell. In certain embodiments, the naked antibody is not glycosylated when expressed by a host cell that does not have its own glycosylation machinery (e.g., a glycosylase). In certain embodiments, the naked antibody is an intact antibody, while in other embodiments, the naked antibody is an antigen binding fragment of an intact antibody, such as a Fab antibody.
The term "conjugated antibody" herein refers to an antibody, which may be monoclonal, chimeric, humanized or human, that may be associated with a pharmaceutically acceptable carrier or diluent.
The term "diabody" herein refers to a bivalent, bispecific antibody that can bind to different epitopes on the same or different antigens.
As used herein, the term "percent (%) sequence identity" refers to the percentage of amino acid (or nucleotide) residues of a candidate sequence that are identical to amino acid (or nucleotide) residues of a reference sequence after aligning the sequences and introducing gaps, if desired, for maximum percent sequence identity (e.g., gaps may be introduced in one or both of the candidate and reference sequences for optimal alignment, and non-homologous sequences may be ignored for comparison purposes). For the purpose of determining percent sequence identity, the alignment may be accomplished in a variety of ways well known to those skilled in the art, for example using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAIi) software. One skilled in the art can determine appropriate parameters for measuring the alignment, including any algorithm that requires maximum alignment over the full length of the sequences being compared. For example, a reference sequence for comparison to a candidate sequence may show that the candidate sequence exhibits 50% -100% sequence identity over the entire length of the candidate sequence or over selected portions of consecutive amino acid (or nucleotide) residues of the candidate sequence. The length of the candidate sequences aligned for comparison purposes may be, for example, at least 30% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%) of the length of the reference sequence. When a position in the candidate sequence is occupied by the same amino acid (or nucleotide) residue as the corresponding position in the reference sequence, then the molecules are identical at that position.
The term "conserved amino acids" herein generally refers to amino acids belonging to the same class or having similar characteristics (e.g., charge, side chain size, hydrophobicity, hydrophilicity, backbone conformation, and rigidity). The following six groups are examples of amino acids that are considered conservative substitutions for each other:
1) Alanine (a), serine (S), threonine (T);
2) Aspartic acid (D), glutamic acid (E);
3) Asparagine (N), glutamine (Q);
4) Arginine (R), lysine (K), histidine (H);
5) Isoleucine (I), leucine (L), methionine (M), valine (V); and
6) Phenylalanine (F), tyrosine (Y), tryptophan (W).
As used herein, the term "specific binding" refers to a binding reaction that determines the presence of an antigen in a heterogeneous population of proteins and other biomolecules that are specifically recognized, for example, by antibodies or antigen-binding fragments thereof. An antibody or antigen binding fragment thereof that specifically binds to an antigen will bind to the antigen with a KD of less than 100 nM. Antibodies or antigen binding fragments thereof that specifically bind to an antigen will bind to the antigen with a KD of up to 100nM (e.g., between 1pM and 100 nM) Antibodies or antigen binding fragments thereof that do not show specific binding to a particular antigen or epitope thereof will show greater than 100nM (e.g., greater than 500nM, 1 μΜ, 100 μΜ, 500 μΜ, or 1 mM) of the particular antigen or epitope thereof, antibodies that specifically immunoreact with a particular protein or carbohydrate can be selected Using a variety of immunoassay formats, e.g., solid phase ELISA immunoassays are routinely used to select Antibodies that specifically immunoreact with a protein or carbohydrate see Harlow & Lane, antibodies ALaboratory Manual, cold Spring Harbor Press, newYork (1988) and Harlow & Lane, using Antibodies A Laboratory Manual, 84, newYork (1999), which describe immunoassay formats and conditions that can be used to determine specific immunoreactivity.
As used herein, the term "antibody conjugate" refers to a conjugate body/conjugate formed by the chemical bonding of an antibody molecule to another molecule, either directly or through a linker. Such as an antibody-drug conjugate (ADC), wherein the drug molecule is said another molecule.
The term "Chimeric Antigen Receptor (CAR)" herein refers to a recombinant protein comprising at least (1) an extracellular antigen binding domain, such as a variable heavy or light chain of an antibody, (2) a transmembrane domain that anchors the CAR into immune effector cells, and (3) an intracellular signaling domain. In certain embodiments, the extracellular antigen-binding domain of the CAR comprises an scFv. The scFv may be derived from the variable region of a fusion antibody. Alternatively or additionally, the scFv may be derived from Fab's (rather than antibodies, e.g. obtained from a Fab library). In certain embodiments, the scFv is fused to a transmembrane domain and then to an intracellular signaling domain.
The term "nucleic acid" herein includes any compound and/or substance comprising a polymer of nucleotides. Each nucleotide consists of a base, in particular a purine or pyrimidine base (i.e. cytosine (C), guanine (G), adenine (a), thymine (T) or uracil (U)), a sugar (i.e. deoxyribose or ribose), and a phosphate group. In general, a nucleic acid molecule is described by a sequence of bases, whereby the bases represent the primary structure (linear structure) of the nucleic acid molecule. The sequence of bases is usually represented as 5 'to 3'. In this context, the term nucleic acid molecule encompasses deoxyribonucleic acid (DNA), including, for example, complementary DNA (cDNA) and genomic DNA, ribonucleic acid (RNA), in particular messenger RNA (mRNA), synthetic forms of DNA or RNA, and polymers comprising a mixture of two or more of these molecules. The nucleic acid molecule may be linear or circular. Furthermore, the term nucleic acid molecule includes both sense and antisense strands, as well as single-and double-stranded forms. Furthermore, the nucleic acid molecules described herein may contain naturally occurring or non-naturally occurring nucleotides. Examples of non-naturally occurring nucleotides include modified nucleotide bases having derivatized sugar or phosphate backbone bonded or chemically modified residues. Nucleic acid molecules also encompass DNA and RNA molecules suitable as vectors for direct expression of the antibodies of the invention in vitro and/or in vivo, e.g., in a host or patient. Such DNA (e.g., cDNA) or RNA (e.g., mRNA) vectors may be unmodified or modified. For example, mRNA can be chemically modified to enhance the stability of the RNA vector and/or expression of the encoded molecule, so that mRNA can be injected into a subject to produce antibodies in vivo (see, e.g., stadler et al, nature Medicine 2017,published online2017, 6-month 12, doi:10.1038/nm.4356 or EP 2 101 823B 1).
As used herein, the term "vector" includes nucleic acid vectors, such as DNA vectors (e.g., plasmids), RNA vectors, viruses, or other suitable replicons (e.g., viral vectors). A variety of vectors have been developed for delivering polynucleotides encoding exogenous proteins into prokaryotic or eukaryotic cells. The expression vectors of the invention contain polynucleotide sequences and additional sequence elements, for example, for expressing proteins and/or integrating these polynucleotide sequences into the genome of mammalian cells. Certain vectors that may be used to express the antibodies and antibody fragments of the invention include plasmids containing regulatory sequences (e.g., promoter and enhancer regions) that direct transcription of genes. Other useful vectors for expressing antibodies and antibody fragments contain polynucleotide sequences that enhance the translation rate of these genes or improve the stability or nuclear export of mRNA produced by gene transcription. These sequence elements include, for example, 5 'and 3' untranslated regions, internal Ribosome Entry Sites (IRES) and polyadenylation signal sites, in order to direct efficient transcription of genes carried on expression vectors. The expression vectors of the invention may also contain polynucleotides encoding markers for selecting cells containing such vectors. Examples of suitable markers include genes encoding antibiotic (e.g., ampicillin, chloramphenicol, kanamycin, or nociceptin) resistance.
The term "host cell" as used herein refers to a cell into which exogenous nucleic acid has been introduced, and includes the progeny of such a cell. Host cells include "transformants" and "transformed cells," which include primary transformed cells and progeny derived therefrom, regardless of the number of passages. The progeny may not be exactly identical in nucleic acid content to the parent cell, but may comprise the mutation. Included herein are mutant progeny that have the same function or biological activity as screened or selected in the initially transformed cells.
The term "pharmaceutical composition" herein refers to a formulation which exists in a form which allows for the biological activity of the active ingredient contained therein to be effective and which does not contain additional ingredients which have unacceptable toxicity to the subject to whom the pharmaceutical composition is administered.
The term "effective amount" herein refers to an amount of a therapeutic agent that is effective to prevent or ameliorate a disease condition or progression of the disease when administered alone or in combination with another therapeutic agent to a cell, tissue or subject. An "effective amount" also refers to an amount of a compound that is sufficient to alleviate symptoms, such as treating, curing, preventing or alleviating a related medical condition, or an increase in the rate of treating, curing, preventing or alleviating such conditions. When an active ingredient is administered to an individual alone, a therapeutically effective dose is referred to as the ingredient alone. When a combination is used, a therapeutically effective dose refers to the combined amounts of the active ingredients that produce a therapeutic effect, whether administered in combination, sequentially or simultaneously.
The term "suitable conditions" herein refers to conditions suitable for culturing a variety of host cells, including eukaryotic cells and prokaryotic cells.
The term "cancer" herein refers to or describes a physiological condition in a mammal that is typically characterized by unregulated cell growth. Included in this definition are benign and malignant cancers.
The term "tumor" herein refers to all neoplastic (neoplastic) cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms "cancer" and "tumor" are not mutually exclusive when referred to herein.
The term "antitumor agent" herein refers to an antitumor drug, which is a class of drugs for treating tumor diseases, and there are chemotherapeutic drugs, biological agents, etc.
Compared with the prior art, the technical scheme of the invention has at least one of the following beneficial effects:
1. compared with alpaca antibodies, the humanized antibody disclosed by the invention has the capability of combining with HSA, reduces immunogenicity while ensuring that the molecular stability and biological functions meet the requirements, and is beneficial to reducing the immune rejection risk of human subjects in use.
2. The humanized antibody of the invention shows good binding capacity with human, mouse and/or monkey serum albumin, which is beneficial to improving the treatment effect and/or developing preclinical animal experiments.
3. In terms of binding to human, murine and/or monkey serum albumin, it was unexpectedly found that the humanized antibodies of the invention are comparable or superior to their parent alpaca antibodies, over conventional humanized antibodies (the binding capacity of conventional humanized antibodies is reduced 2-3 fold compared to the parent antibodies).
Unless defined otherwise herein, scientific and technical terms used in connection with the present invention shall have the meaning as understood by one of ordinary skill in the art.
FIG. 1 is an electrophoresis diagram of a nested PCR two-round amplification alpaca nanobody gene sequence, and lane M is a protein Marker band.
FIG. 2 is a diagram showing the number of transformants, wherein the left panel shows the number of transformants in bacterial liquid diluted 1000-fold, and the right panel shows the number of transformants diluted 10000-fold.
FIG. 3 is an electrophoretogram of colony PCR for the insertion rate detection of clones after electrotransformation, lane M being a protein Marker band.
FIG. 4 shows SDS-PAGE and SEC-HPLC purity assays after purification of HSA control antibodies.
FIG. 5 is a chart showing the SEC-HPLC method for detecting the purity of the alpaca VHH-Fc antibody of the present invention.
The invention will be further described with reference to specific embodiments, and advantages and features of the invention will become apparent from the description. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
The present embodiments are merely examples and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Example 1 screening for human serum albumin nanobodies
1.1 detection of immune and serum titers of alpaca
1 Alpaca (Alpaca) aged 1.5-3 years was selected, and 10ml was collected before immunization and left as negative control serum. The first immunization was performed by subcutaneous injection after 0.5mg of human serum albumin (Chengdu Rong, national drug standard S10940024) was thoroughly mixed with Freund' S adjuvant (Sigma, F5881) using the prime dose doubling principle. Three weeks later, a second immunization was performed, 0.25mg of protein was mixed with Freund's adjuvant and then subcutaneously immunized, and serum was taken one week later for potency measurement. Third immunization 0.25mg protein was mixed with Freund's adjuvant and then subcutaneously immunized, and serum was taken one week later for potency measurement. To increase the probability of cross-binding of human and mouse, the fourth immunization was performed with a 0.25mg each of human serum albumin and mouse serum albumin (Alpha diagnostic, ALB 14-N-10) mixed together, and a 0.5mg challenge immunization after one week. Antibody titers and specificities of serum against human serum albumin were measured by enzyme-linked immunosorbent assay (ELISA), and the results of serum titers of alpaca from the third and fourth immunizations are shown in Table 1, where the data are OD450nm values.
TABLE 1 ELISA detection of serum antibody titers of alpaca after immunization with human serum albumin
1.2 construction of anti-human serum Albumin nanobody library
The peripheral blood of alpaca after the third and fourth immunizations was collected for 50mL and PBMCs were isolated using lymphocyte separation fluid. Total RNA after three and four immunizations was extracted with RNAiso Plus reagent (Takara, 9108/9109). According to the reverse transcription kit PrimeScript TM II 1st Strand cDNA Synthesis Kit (Takara, 6210A) protocol, 5. Mu.g RNA was co-transcribed. The nanobody (VHH) fragments were amplified using nested PCR with cDNA as template. FIG. 1 shows the results of the first and second rounds of amplification of VHH fragments, showing that the size of the target band after the first round of amplification is about 750bp and that after the second round of amplification is about 500bp. After purification of the PCR product, it was ligated into phage display vector pComb3Xss (Chengdu Parker, P001) using restriction enzyme SfiI (NEB, R0123L). Then the ligation product was electrotransformed into TG1 competent cells, 10 times of shock transformation were performed, 1mL of 2YT medium (Industry, A507019-0250) was added to the cuvette immediately after the shock for resuscitation, the shock product was aspirated and the cuvette was washed with 2YT medium (Industry, A507019-0250) to obtain 100mL in total TG1 cells resuscitate the product. Recovering TG1 cells at 37deg.C and 180rpm for 45min, and gradient diluting 100ml TG1 bacteria solution for 10 min 3 Double sum 10 4 The number of transformants in the nanobody library was determined by doubling and 10 3 And 10 4 The diluted TG1 bacterial liquid is coated on a 90mm plate, the rest bacterial liquid is centrifuged, 8mL 2YT culture medium (Producer, A507019-0250) is added for resuspension, and the bacterial liquid is coated on 8 200mm plates. The results of the number of transformants in gradient dilution are shown in FIG. 2, in the panel "NB116 10" for determining the number of transformants in the nanobody pool -4 "200 clones in total, calculated as the size of the pool size was 2.0X10 9 . FIG. 3 shows that 48 clones were randomly picked from the pool of transformants number titer plates for identification and the DNA band size of the protein of interest was approximately 500bp. The results showed that 48 clones were all positive, indicating an insertion rate of 100%.
First round amplification of the upstream primer LD-F:
first round amplification of the downstream primer CH2-R:
the second round of amplification upstream Primer is Primer F:
second round amplification of the downstream Primer R1:
second round amplification of the downstream Primer R2:
1.3 panning against human serum Albumin nanobody
Diluting the antigen molecule (Dongren chemical, LK 55) marked by biotin with carbonate buffer solution with pH value of 9.6 to a final concentration of 5 mug/mL, adding 100 mug/hole into enzyme-labeled hole, and coating at 4 ℃ overnight; the next day, 300. Mu.L of 3% OVA-PBS blocking solution was added to each well, after blocking for 1h at 37℃100. Mu.L of phage library was added and incubated for 1h at 37 ℃; followed by 6 washes with PBST and 2 washes with PBS to wash away unbound phage. Finally, 100. Mu.L Gly-HCl eluent is added, and incubated at 37 ℃ for 8min, and specifically bound phage is eluted. The eluted phage is continuously infected with TG1 strain, and positive phage is continuously enriched in the process of panning through multiple rounds of panning so as to screen out nano antibodies with good specificity and high affinity.
1.4 screening of specific individual Positive clones by phage ELISA
After panning, 96 clones were randomly selected for inoculation in 2YT medium (Bio, a 507019-0250), followed by 1:20 was added to M13K07 phage (NEB, N0315S) and incubated at 37℃for 45min. The next day the culture supernatant was taken for monoclonal ELISA identification. The albumin antigen of target molecule human, mouse and monkey was diluted with carbonate buffer solution with pH 9.6 to a final concentration of 2. Mu.g/mL, added to the enzyme-labeled wells at 100. Mu.L/well, and coated overnight at 4 ℃. Then 35. Mu.L of phage culture supernatant and 1:1000 dilution of horseradish peroxidase-labeled anti-M13 antibody (Proprietary, 11973-MM 05T-H) were added to each well, washed, followed by addition of TMB chromogenic solution (Soxhobao, PR 1200) for development and densitometry at 450 nm. Positive clones were selected for simultaneous binding to human, murine, and monkey albumin (Abcam, ab 184894) for sequencing. Through multiple rounds of optimization and screening, 3 positive clones capable of simultaneously recognizing human, mouse and monkey albumin are obtained and named sdAb-76, sdAb-220 and sdAb-350 respectively. The CDRs of the sequences are analyzed by KABAT, chothia or IMGT software respectively, and the corresponding sequence information is shown in the following tables 2-3, wherein the table 2 shows the antibody sequences expressed by amino acids of 3 alpaca nanobody molecules, and the table 3 shows the results of IMGT, kabat and Chothia analysis of the CDRs of the 3 alpaca nanobody molecules.
TABLE 2 amino acid specific sequence information of anti-HSA alpaca nanobody
TABLE 3 analysis of CDRs specific sequence information of HSA alpaca nanobody by IMGT, KABAT and Chothia software
Example 2 preparation of control antibodies
2.1 Recombinant expression of HSA control antibodies
The control antibody used in the present invention was obtained from the block structure of Vobarilizumab with anti-HSA antibody function (the sequence is from patent publication WO2018/029182 by Ablynx Co., ltd.) and the sequence is shown in Table 4 below. The control antibody variable region sequence was cloned into pTT5 vector (Youbao organism, VT 2202) with human Fc hinge region and constant region sequences, fusion expressed with the antibody constant region to form VHH-Fc expression sequence, and plasmids were prepared. Antibody plasmids were transiently transfected into Expi293F (Gibco, A14527) cells by PEI (Polysciences, 24765-1), and supernatants were collected after 7 days of culture and antibody purified as in example 2.2. The resulting HSA control antibody was designated aHSA-Fc. As shown in FIG. 4, the aHSA-Fc antibody had a molecular weight of about 40kD in the reduced state and about 80kD in the non-reduced state, and was detected to have a purity of 95% by the SEC-HPLC method.
TABLE 4 control antibody sequence listing
Remarks: * Represents a stop codon.
2.2 Protein A affinity chromatography purification Fc tag nano antibody
The cell culture supernatant expressing the antibody was first harvested by high-speed centrifugation. The protein A (Bognon, AA 0273) protein column was washed 3-5 column volumes with 0.1M NaOH and then 3-5 column volumes with pure water. The column was equilibrated 3-5 column volumes using a 1 XPBS (pH 7.4) buffer system as an equilibration buffer. The cell supernatants were loaded for binding at low flow rates, the flow rates were controlled to allow retention times of about 1min or longer, and after binding, the column was washed 3-5 column volumes with 1 XPBS (pH 7.4) until UV absorbance fell back to baseline. Sample elution was performed using 50mM citric acid/sodium citrate (pH 3.0-3.5) buffer, elution peaks were collected according to UV detection, and the eluted product was rapidly adjusted to pH 5-6 using 1M Tris-HCl (pH 8.0) for buffer storage. For the eluted product, solution displacement may be performed by methods well known to those skilled in the art, such as ultrafiltration concentration using an ultrafiltration tube and solution displacement to a desired buffer system, or desalting using a molecular exclusion column such as G-25 to a desired buffer system, or removing the polymer component in the eluted product using a high resolution molecular exclusion column such as Superdex 200 to increase the sample purity.
Example 3 recombinant nanobody expression purification and affinity detection
3.1 expression purification of recombinant nanobodies
The obtained alpaca nanobody sequences were cloned onto eukaryotic expression vectors pTT5 (Youbao organism, VT2202, fc sequences see Table 4) with Fc tags respectively, PEI (Polysciences, 24765-1) transiently transferred the Expi293F cells (Gibco, A14527), the supernatants were collected after 6 days of culture, and the antibodies with Fc tags eluted from the protein A chromatographic column were collected by affinity purification of protein A protein (Boguron, AA 0273) to obtain the corresponding recombinant nanobodies (VHH-Fc) named ch-sdAb-76, ch-sdAb-220 and ch-sdAb-350 respectively. The antibodies obtained by purification are detected by SEC-HPLC method, and the result of one-step purification of Protein A is shown in figure 5, which shows that the purity of three antibodies is more than 95%.
3.2 affinity assay of recombinant nanobodies
The binding strength of the antibodies to the antigen was detected using a BIAcore 8K instrument using the Protein A capture method. First, protein A was immobilized on CM4 chip (manufacturer: GE, cat. No. BR-1005-34) by amino coupling method, after mixing NHS and EDC with HBS-EP+pH7.4 as mobile phase according to the direction of Amine Coupling Kit kit (manufacturer: GE, cat. No. BR 100633), the chip was activated for about 600 seconds, protein A was diluted to 50. Mu.g/mL with 10mM sodium acetate pH4.5, injected for 600 seconds, and finally the remaining activation sites were blocked with ethanolamine. Then, determining the affinity of the antibody and the antigen by adopting a multi-cycle dynamics method, in each cycle, firstly capturing the antibody to be detected by using a Protein A chip, then injecting antigen Protein with single concentration, recording the combination and dissociation processes of the antibody and the antigen Protein, and finally finishing chip regeneration by using Glycine pH1.5, wherein the mobile phase is HBS-EP+ (10mM HEPES,150mM NaCl,3mM EDTA, 0.05%surfactant P20), the flow rate is 30 mu L/min, the regeneration time is 30s, and the detection temperature is 25 ℃; finally, the data were analyzed according to the 1:1 binding model, fitting antibody antigen binding kinetic parameters including binding rate constant ka, dissociation rate constant KD, equilibrium dissociation constant KD, maximum binding signal Rmax.
The binding rate (Ka), dissociation rate (Kd) and binding affinity (Kd) of the 3 recombinant nanobodies to human, mouse and monkey albumin are shown in table 5. Wherein, the affinity of the three recombinant nano antibodies against human, mouse and monkey serum albumin is better than that of the control antibody aHSA-Fc (SEQ ID NO. 57), as shown in Table 5, the three recombinant nano antibodies are combined with human, mouse and monkey serum albumin, the affinity with human serum albumin is above 6.87E-09M, the affinity with monkey serum albumin is above 7.10E-09M, and the affinity with mouse serum albumin is above 1.04E-08M.
TABLE 5 SPR (biacore) detection of affinity of recombinant nanobodies to human, monkey, mouse serum albumin
EXAMPLE 4 nanobody humanization
4.1 humanized design of alpaca nanobody
The variable region germline gene database and MOE (Molecular Operating Environment ) software of human antibody in IMGT (http:// IMGT. Cines. FR) database are respectively selected and used as templates for heavy chain variable region germline genes with high homology with the nanobody, and CDRs sequences of the nanobody based on Kabat naming method are respectively transplanted into corresponding human templates to form variable region sequences with the sequence of 'FR 1-CDR1-FR2-CDR2-FR3-CDR3-FR 4'. Humanized templates of the sdAb-76 alpaca nanobody are IGHV3-23 x 04 and IGHJ2 x 01, and humanized templates of the sdAb-350 and sdAb-220 alpaca nanobody are IGHV3-23 x 04 and IGHJ3 x 01. CDRs of alpaca antibodies sdAb-76, sdAb-350 and sdAb-220 were transplanted into their humanized templates, respectively, and the amino acid sequences of the humanized templates and the amino acid sequences of the 3 humanized antibodies are shown in Table 6.
TABLE 6 amino acid specific sequence information of humanized templates and humanized antibodies
4.2 humanized antibody back mutation design of hu-sdAb76
The key amino acid in the FR region sequence of the hu-sdAb76 humanized antibody is subjected to back mutation to be the amino acid corresponding to the alpaca antibody, so that the original affinity is ensured, and details of mutation points after specific back mutation (the back mutation points are numbered in natural sequence) and specific amino acid sequences are shown in tables 7-8.
TABLE 7 mutation Point cases of the back mutation of hu-sdAb76 humanized antibodies
Antibody name | Sequence numbering | Mutation point |
hu-sdAb76-H1 | SEQ ID NO.7 | Graft(IGHV3-23*04)+S30N,V37F,I70V,A97R,K98Q,W109R |
hu-sdAb76-H2 | SEQ ID NO.8 | Graft(IGHV3-23*04)+S30N,V37F,I70V,A97R,K98Q,W109R,E1Q |
hu-sdAb76-H3 | SEQ ID NO.9 | Graft(IGHV3-23*04)+S30N,V37F,I70V,A97R,K98Q,W109R,S75A |
hu-sdAb76-H4 | SEQ ID NO.10 | Graft(IGHV3-23*04)+S30N,V37F,I70V,A97R,K98Q,W109R,Q82E |
hu-sdAb76-H5 | SEQ ID NO.11 | Graft(IGHV3-23*04)+S30N,V37F,I70V,A97R,K98Q,W109R,S85N |
hu-sdAb76-H6 | SEQ ID NO.12 | Graft(IGHV3-23*04)+S30N,V37F,I70V,A97R,K98Q,W109R,L114Q |
Note that: graft (IGHV 3-23X 04) represents the implantation of alpaca antibody CDRs into human germline FR region sequences; A97R represents the mutation of A at position 97 of Graft (IGHV 3-23.04) to R, and so on.
TABLE 8 amino acid sequence of the back mutation of hu-sdAb76 humanized antibodies
Note that: the bolded parts represent mutation points
4.3 humanized antibody back mutation design of hu-sdAb220
The key amino acid in the FR region sequence of the hu-sdAb220 humanized antibody is subjected to back mutation to be the amino acid corresponding to the alpaca antibody, so that the original affinity is ensured, and details of mutation points after specific back mutation (the back mutation points are numbered in natural sequence) and specific amino acid sequences are shown in tables 9-10.
TABLE 9 mutation Point cases of the back mutation of the hu-sdAb220 humanized antibody
Note that: graft (IGHV 3-23X 04) represents the implantation of alpaca antibody CDRs into human germline FR region sequences; E1Q represents the mutation of E at position 1 of Graft (IGHV 3-23.04) to Q, and so on.
TABLE 10 amino acid sequence of the back mutation of hu-sdAb220 humanized antibodies
Note that: the bolded parts represent mutation points
4.4 humanized antibody back mutation design of hu-sdAb350
The key amino acids in the FR region sequence of the hu-sdAb350 humanized antibody are subjected to back mutation to amino acids corresponding to the alpaca antibody, so that the original affinity is ensured, and details of mutation points after specific back mutation (the back mutation points are numbered in natural sequence) and specific amino acid sequences are shown in tables 11-12.
TABLE 11 mutation Point cases of the back mutation of hu-sdAb350 humanized antibodies
Antibody name | Sequence numbering | Mutation point |
hu-sdAb350-H1 | SEQ ID NO.20 | Graft(IGHV3-23*04)+A97S,K98I |
hu-sdAb350-H2 | SEQ ID NO.21 | Graft(IGHV3-23*04)+A97S,K98I,W104S |
hu-sdAb350-H3 | SEQ ID NO.22 | Graft(IGHV3-23*04)+V2L,A97S,K98I,W104S |
hu-sdAb350-H4 | SEQ ID NO.23 | Graft(IGHV3-23*04)+T28A,A97S,K98I,W104S |
hu-sdAb350-H5 | SEQ ID NO.24 | Graft(IGHV3-23*04)+V2L,T28A,A97S,K98I,W104S |
hu-sdAb350-H6 | SEQ ID NO.25 | Graft(IGHV3-23*04)+R87K,A88P,A97S,K98I,W104S |
hu-sdAb350-H7 | SEQ ID NO.26 | Graft(IGHV3-23*04)+V2L,T28A,S75A,A97S,K98I,W104S |
hu-sdAb350-H8 | SEQ ID NO.27 | Graft(IGHV3-23*04)+V2L,T28A,R87K,A88P,A97S,K98I,W104S |
Note that: graft (IGHV 3-23X 04) represents the implantation of alpaca antibody CDRs into human germline FR region sequences; A97S indicates that A at position 97 of Graft (IGHV 3-23.04) is mutated to S, and so on.
TABLE 12 amino acid sequence of the back mutation of hu-sdAb350 humanized antibodies
Note that: the bolded parts represent mutation points
EXAMPLE 5 expression purification and affinity determination of humanized nanobodies
5.1 expression purification of humanized nanobodies
After the humanized antibody variable region sequence is synthesized (completed by Shanghai, inc.) it is cloned into pTT5 vector (Youbao organism, VT 2202) with human Fc hinge region and constant region sequence, and fusion expressed with antibody constant region to form VHH-Fc expression sequence, and plasmid is prepared. Antibody plasmids were transiently transfected into Expi293F (Gibco, A14527) cells by PEI (Polysciences, 24765-1), and supernatants were collected after 7 days of culture and antibody purified as in example 2.2.
5.2 Affinity assay for hu-sdAb76 humanized antibodies
After purification of the expression of the various hu-sdAb76 humanized antibodies finally obtained, the affinity of the humanized antibodies to human, monkey and mouse serum albumin was determined separately according to the method of example 3.2, and the specific affinity values are shown in table 13. Through back mutation, the humanized antibody hu-sdAb76-H4 maintains an affinity level with the chimeric antibody, substantially comparable to the chimeric control antibody.
TABLE 13 SPR (biacore) detection of affinity of hu-sdAb76 humanized antibodies to human, monkey, mouse serum albumin
Antibody name | Antigens | ka(1/Ms) | kd(1/s) | KD(M) |
ch-sdAb-76 | Human serum albumin | 5.12E+05 | 1.86E-04 | 3.64E-10 |
ch-sdAb-76 | Monkey serum albumin | 5.27E+05 | 1.40E-03 | 2.65E-09 |
ch-sdAb-76 | Mouse serum albumin | 1.30E+05 | 5.78E-04 | 4.44E-09 |
hu-sdAb76-H1 | Human serum albumin | 1.47E+05 | 2.53E-04 | 1.71E-09 |
hu-sdAb76-H1 | Monkey serum albumin | 3.25E+05 | 6.22E-03 | 1.92E-08 |
hu-sdAb76-H1 | Mouse serum albumin | No binding | No binding | No binding |
hu-sdAb76-H2 | Human serum albumin | 1.37E+05 | 2.35E-04 | 1.72E-09 |
hu-sdAb76-H2 | Monkey serum albumin | 2.24E+05 | 4.02E-03 | 1.80E-08 |
hu-sdAb76-H2 | Mouse serum albumin | 4.00E+04 | 3.57E-04 | 8.92E-09 |
hu-sdAb76-H3 | Human serum albumin | 1.48E+05 | 2.89E-04 | 1.95E-09 |
hu-sdAb76-H3 | Monkey serum albumin | 2.52E+05 | 5.23E-03 | 2.08E-08 |
hu-sdAb76-H3 | Mouse serum albumin | 3.30E+04 | 4.11E-04 | 1.25E-08 |
hu-sdAb76-H4 | Human serum albumin | 4.74E+05 | 1.70E-04 | 3.60E-10 |
hu-sdAb76-H4 | Monkey serum albumin | 4.45E+05 | 1.59E-03 | 3.58E-09 |
hu-sdAb76-H4 | Mouse serum albumin | 7.50E+04 | 6.82E-04 | 9.09E-09 |
hu-sdAb76-H5 | Human serum albumin | 1.48E+05 | 2.99E-04 | 2.02E-09 |
hu-sdAb76-H5 | Monkey serum albumin | 2.18E+05 | 5.01E-03 | 2.30E-08 |
hu-sdAb76-H5 | Mouse serum albumin | 2.26E+04 | 5.41E-04 | 2.39E-08 |
hu-sdAb76-H6 | Human serum albumin | 1.49E+05 | 3.12E-04 | 2.10E-09 |
hu-sdAb76-H6 | Monkey serum albumin | 2.31E+05 | 5.43E-03 | 2.36E-08 |
hu-sdAb76-H6 | Mouse serum albumin | 2.68E+04 | 5.02E-04 | 1.87E-08 |
5.3 Affinity assay for hu-sdAb220 humanized antibodies
After purification of the finally obtained humanized antibodies of hu-sdAb220 expression, the affinity of the antibodies to human, monkey, mouse, rat serum albumin, respectively, was determined according to the method of example 3.2, and the specific affinity values are shown in table 14. The results show that: all hu-sdAb220 humanized antibodies remained at levels comparable to the chimeric control antibodies through back-mutation, binding to human serum albumin and monkey serum albumin. However, the hu-sdAb220 humanized antibodies have weaker binding to mouse serum albumin than chimeric antibodies. Presumably, this is due to the fact that the binding epitope of the hu-sdAb220 nanobody to mouse albumin is more offset from the CDR regions, and more FR regions are involved in protein binding.
TABLE 14 SPR (biacore) detection of affinity of hu-sdAb220 humanized antibodies to human, monkey, mouse serum albumin
Antibody name | Antigens | ka(1/Ms) | kd(1/s) | KD(M) |
ch-sdAb-220 | Human serum albumin | 2.47E+05 | 9.98E-04 | 4.04E-09 |
ch-sdAb-220 | Monkey serum albumin | 2.80E+05 | 1.98E-03 | 7.10E-09 |
ch-sdAb-220 | Mouse serum albumin | 5.34E+04 | 2.20E-04 | 4.13E-09 |
hu-sdAb220-H1 | Human serum albumin | 3.70E+05 | 1.26E-03 | 3.40E-09 |
hu-sdAb220-H1 | Monkey serum albumin | 3.61E+05 | 2.16E-03 | 5.98E-09 |
hu-sdAb220-H1 | Mouse serum albumin | 2.58E+04 | 4.39E-04 | 1.70E-08 |
hu-sdAb220-H2 | Human serum albumin | 3.62E+05 | 1.34E-03 | 3.70E-09 |
hu-sdAb220-H2 | Monkey serum albumin | 3.54E+05 | 2.27E-03 | 6.41E-09 |
hu-sdAb220-H2 | Mouse serum albumin | 2.16E+04 | 3.86E-04 | 1.78E-08 |
hu-sdAb220-H3 | Human serum albumin | 3.79E+05 | 1.34E-03 | 3.54E-09 |
hu-sdAb220-H3 | Monkey serum albumin | 3.65E+05 | 2.26E-03 | 6.19E-09 |
hu-sdAb220-H3 | Mouse serum albumin | 2.82E+04 | 5.35E-04 | 1.89E-08 |
hu-sdAb220-H4 | Human serum albumin | 3.68E+05 | 1.31E-03 | 3.57E-09 |
hu-sdAb220-H4 | Monkey serum albumin | 3.65E+05 | 2.22E-03 | 6.08E-09 |
hu-sdAb220-H4 | Mouse serum albumin | 2.39E+04 | 3.08E-04 | 1.29E-08 |
hu-sdAb220-H5 | Human serum albumin | 3.68E+05 | 1.11E-03 | 3.02E-09 |
hu-sdAb220-H5 | Monkey serum albumin | 3.57E+05 | 1.92E-03 | 5.38E-09 |
hu-sdAb220-H5 | Mouse serum albumin | 2.53E+04 | 3.01E-04 | 1.19E-08 |
hu-sdAb220-H6 | Human serum albumin | 3.84E+05 | 1.17E-03 | 3.05E-09 |
hu-sdAb220-H6 | Monkey serum albumin | 3.72E+05 | 2.04E-03 | 5.49E-09 |
hu-sdAb220-H6 | Mouse serum albumin | 3.10E+04 | 4.36E-04 | 1.41E-08 |
hu-sdAb220-H7 | Human serum albumin | 3.64E+05 | 1.30E-03 | 3.56E-09 |
hu-sdAb220-H7 | Monkey serum albumin | 3.53E+05 | 2.24E-03 | 6.35E-09 |
hu-sdAB220-H7 | Mouse serum albumin | 2.34E+04 | 3.64E-04 | 1.55E-08 |
Considering the closer homology between mice and rats, we further determined the affinity of antibodies to rat serum albumin according to the method of example 3.2, and the specific affinity values are shown in Table 15. The results show that: the affinity of the control antibody aHSA-Fc for rat serum albumin was very weak, only 5.00E-07M. The hu-sdAb220 was back mutated, and all humanized antibodies retained levels of affinity for rats comparable to chimeric antibodies.
TABLE 15 SPR (biacore) detection of affinity of hu-sdAb220 humanized antibodies to rat serum albumin
Antibody name | Antigens | ka(1/Ms) | kd(1/s) | KD(M) |
ch-sdAb-220 | Rat serum albumin | 1.22E+06 | 3.31E-02 | 2.71E-08 |
hu-sdAb220-H1 | Rat serum albumin | 1.05E+06 | 3.16E-02 | 3.01E-08 |
hu-sdAb220-H2 | Rat serum albumin | 1.20E+06 | 3.40E-02 | 2.84E-08 |
hu-sdAb220-H3 | Rat serum albumin | 1.12E+06 | 3.32E-02 | 2.95E-08 |
hu-sdAb220-H4 | Rat serum albumin | 1.20E+06 | 2.94E-02 | 2.46E-08 |
hu-sdAb220-H5 | Rat serum albumin | 1.20E+06 | 3.01E-02 | 2.51E-08 |
hu-sdAb220-H6 | Rat serum albumin | 1.11E+06 | 3.30E-02 | 2.97E-08 |
hu-sdAb220-H7 | Rat serum albumin | 8.35E+05 | 2.24E-02 | 2.68E-08 |
aHSA-Fc control | Rat serum albumin | 6.84E+04 | 3.42E-02 | 5.00E-07 |
5.4 Affinity assay for hu-sdAb350 humanized antibodies
After purification of the finally obtained humanized antibodies of the hu-sdAb350 expression, the affinity of the antibodies for human, monkey and mouse serum albumin, respectively, was determined according to the method of example 3.2, and the specific affinity values are shown in table 16. The results show that: the affinity of the humanized antibodies was maintained at a level comparable to that of the chimeric control antibody except for the hu-sdAb350-H1 by back-mutation.
TABLE 16 SPR (biacore) detection of affinity of hu-sdAb350 humanized antibodies to human, monkey, mouse serum albumin
Antibody name | Antigens | ka(1/Ms) | kd(1/s) | KD(M) |
ch-sdAb-350 | Human serum albumin | 1.53E+05 | 1.05E-03 | 6.87E-09 |
ch-sdAb-350 | Monkey serum albumin | 1.50E+05 | 8.80E-04 | 5.85E-09 |
ch-sdAb-350 | Mouse serum albumin | 8.19E+04 | 8.56E-04 | 1.04E-08 |
hu-sdAb350-H1 | Human serum albumin | 1.16E+05 | 1.73E-02 | 1.50E-07 |
hu-sdAb350-H1 | Monkey serum albumin | 5.63E+05 | 1.45E-02 | 2.58E-08 |
hu-sdAb350-H1 | Mouse serum albumin | 4.74E+04 | 1.21E-03 | 2.55E-08 |
hu-sdAb350-H2 | Human serum albumin | 1.34E+05 | 7.90E-04 | 5.88E-09 |
hu-sdAb350-H2 | Monkey serum albumin | 1.28E+05 | 6.62E-04 | 5.18E-09 |
hu-sdAb350-H2 | Mouse serum albumin | 7.69E+04 | 1.17E-03 | 1.53E-08 |
hu-sdAb350-H3 | Human serum albumin | 1.40E+05 | 1.08E-03 | 7.70E-09 |
hu-sdAb350-H3 | Monkey serum albumin | 1.32E+05 | 9.29E-04 | 7.02E-09 |
hu-sdAb350-H3 | Mouse serum albumin | 7.65E+04 | 1.06E-03 | 1.39E-08 |
hu-sdAb350-H4 | Human serum albumin | 1.33E+05 | 7.39E-04 | 5.54E-09 |
hu-sdAb350-H4 | Monkey serum albumin | 1.27E+05 | 6.31E-04 | 4.95E-09 |
hu-sdAb350-H4 | Mouse serum albumin | 7.56E+04 | 1.17E-03 | 1.55E-08 |
hu-sdAb350-H5 | Human serum albumin | 1.42E+05 | 1.02E-03 | 7.14E-09 |
hu-sdAb350-H5 | Monkey serum albumin | 1.34E+05 | 8.89E-04 | 6.63E-09 |
hu-sdAb350-H5 | Mouse serum albumin | 7.65E+04 | 1.05E-03 | 1.37E-08 |
hu-sdAb350-H6 | Human serum albumin | 1.34E+05 | 7.72E-04 | 5.78E-09 |
hu-sdAb350-H6 | Monkey serum albumin | 1.26E+05 | 6.50E-04 | 5.14E-09 |
hu-sdAb350-H6 | Mouse serum albumin | 7.77E+04 | 1.17E-03 | 1.51E-08 |
hu-sdAb350-H7 | Human serum albumin | 1.37E+05 | 1.05E-03 | 7.68E-09 |
hu-sdAb350-H7 | Monkey serum albumin | 1.65E+05 | 9.82E-04 | 5.95E-09 |
hu-sdAb350-H7 | Mouse serum albumin | 7.66E+04 | 1.03E-03 | 1.34E-08 |
hu-sdAb350-H8 | Human serum albumin | 1.43E+05 | 1.02E-03 | 7.13E-09 |
hu-sdAb350-H8 | Monkey serum albumin | 1.35E+05 | 8.96E-04 | 6.63E-09 |
hu-sdAb350-H8 | Mouse serum albumin | 7.82E+04 | 1.03E-03 | 1.32E-08 |
Claims (24)
- An isolated nanobody or antigen-binding fragment that binds Human Serum Albumin (HSA), wherein the antibody or antigen-binding fragment comprises a combination of CDRs of a heavy chain variable region comprising: HCDR1, HCDR2 and HCDR3; the HCDR1, HCDR2 and HCDR3 have any sequence combination selected from the group consisting of:each of HCDR1, HCDR2 and HCDR3 is encoded according to a current analytical method of KABAT, chothia or IMGT;preferably, the substitution is a conservative amino acid substitution.
- The nanobody or antigen-binding fragment of claim 1, wherein,(1) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.31, 32 and 33;(2) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.34, 35 and 36;(3) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.37, 38 and 36;(4) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.39, 40 and 41;(5) The HCDR1, HCDR2 and HCDR3 are respectively shown as sequences shown in SEQ ID NO.42, 43 and 44;(6) The HCDR1, HCDR2 and HCDR3 are respectively shown as sequences shown in SEQ ID NO.45, 46 and 44;(7) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.47, 48 and 49;(8) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.50, 51 and 52;(9) The HCDR1, HCDR2 and HCDR3 are respectively shown as SEQ ID NO.53, 54 and 52; or alternatively, the first and second heat exchangers may be,(10) The HCDR1, HCDR2 and HCDR3 are a sequence combination having 1, 2, 3 or more amino acid insertions, deletions and/or substitutions compared to a sequence combination of (1) - (9) above; substitutions are preferred, more preferably conservative amino acid residue substitutions.
- The nanobody or antigen-binding fragment of any one of claims 1-2, wherein the framework region of the heavy chain variable region of the nanobody or antigen-binding fragment is derived from a human germline heavy chain, wherein:(1) The framework region sequence is derived from the combined sequence of human germline heavy chains IGHV3-23 x 04 and IGHJ2 x 01; which comprises SEQ ID NO:28, the FR1, FR2, FR3 regions of igfv 3-23 x 04 and SEQ ID NO:29 to igfj 2 x 01;(2) The framework region sequence is derived from the combined sequence of human germline heavy chains IGHV3-23 x 04 and IGHJ3 x 01; which comprises SEQ ID NO:28, the FR1, FR2, FR3 regions of igfv 3-23 x 04 and SEQ ID NO:30, the FR4 region of IGHJ3 x 01.
- The nanobody or antigen-binding fragment of claim 3, wherein the framework region of the heavy chain variable region of the nanobody or antigen-binding fragment further comprises one or more mutations selected from the group consisting of:(1) E1Q, S30N, V F, I70V, S3756A, Q82E, S85N, A97R, K98Q, W109R or L114Q; preferably including S30N, V37F, I70V, A97R, K98Q and W109R; or preferably S30N, V37F, I70V, A97R, K98Q, W109R and E1Q; or preferably comprises S30N, V37F, I70V, A97R, K98Q, W109R and S75A; or preferably S30N, V37F, I70V, A97R, K98Q, W109R and Q82E; or preferably comprises S30N, V37F, I70V, A97R, K98Q, W109R and S85N; or preferably comprises S30N, V37F, I70V, A97R, K98Q, W109R and L114Q;(2) E1Q, A23V, F V, T28D, S R, S6275A, R87K, A88F, T M, A97V, K98Q, W P or M116Q; preferably including E1Q, F27V, T D, S R, S75A, T91M, A97V, K98Q, W P and M116Q; preferably including F27V, T28D, S30R, S A, T91M, A97V, K3598Q, W111P and M116Q; preferably including F27V, T28D, S R, T91M, A97V, K98Q, W P and M116Q; preferably including F27V, T28D, S30R, R87K, A88F, T91M, A97V, K98Q, W P and M116Q; preferably including E1Q, A23V, F27V, T D, S30R, S A, A97V, K Q and W111P; preferably comprising a23V, F27V, T28D, S R, S30 6275A, A97V, K Q and W111P; preferably including F27V, T28D, S30R, R87K, A F, T91M, A97V, K Q and W111P;(3) V2L, T28A, S75A, R87K, A88P, A97S, K I or W104S; preferably comprising a97S and K98I; preferably comprising a97S, K I and W104S; preferably comprising V2L, A97S, K I and W104S; preferably including T28A, A97S, K I and W104S; preferably comprising V2L, T28A, A97S, K98I and W104S; preferably, R87K, A88P, A97S, K98I and W104S; preferably comprising V2L, T28A, S A, A97S, K98I and W104S; preferably V2L, T28A, R87K, A88P, A97S, K98I and W104S.
- The nanobody or antigen-binding fragment of any one of claims 1-4, wherein said nanobody or antigen-binding fragment comprises:(1) The variable region has a sequence shown in SEQ ID NO 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27;(2) An amino acid sequence having at least 90% identity, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity, to the sequence shown in (1) above; or alternatively, the first and second heat exchangers may be,(3) The framework regions of the nanobody or antigen-binding fragment have at least 90% identity, preferably at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity, to the framework regions of the amino acid sequences shown in SEQ ID NOs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26 or 27.
- Nanobody or antigen-binding fragment according to any one of claims 1 to 5, characterized in that it binds to human serum albumin, monkey serum albumin and/or rat serum albumin; alternatively, the antibody or antigen binding fragment binds to human serum albumin, monkey serum albumin, and/or rat serum albumin with a dissociation constant (KD) of less than 1.00E-8M, 2.00E-8M, 3.00E-8M, 1.00E-9M, 2.00E-09M, 3.00E-9M, 4.00E-09M, 5.00E-09M, 6.00E-09M, 7.00E-09M, 8.00E-09M, 9.00E-09M, 1.00E-10M, 2.00E-10M, 3.00E-10M, 4.00E-10M, 5.00E-10M, 6.00E-10M, 7.00E-10M, 8.00E-10M, 9.00E-10M, 1.00E-11M, 2.00E-11M, 3.00E-11M, 4.00E-11M, 1.00E-10M, 2.00E-11M, 3.00E-12.00E-12M, 12.00E-12M, 3.00E-12.00E-12M;alternatively, the nanobody or antigen-binding fragment binds to mouse serum albumin or does not bind.
- The nanobody or antigen-binding fragment of any one of claims 1-6, wherein the antibody or antigen-binding fragment comprises the sequence of the constant region of any one of antibodies IgG1, igG2, igG3, igG4, igA, igM, igE, or IgD; preferably comprising the sequences of the constant regions of antibodies IgG1, igG2, igG3 or IgG 4.
- The nanobody or antigen-binding fragment of any one of claims 1-7, wherein the antibody or antigen-binding fragment further comprises an antibody constant region sequence in the absence of a CH1 fragment.
- The nanobody or antigen-binding fragment of any one of claims 1-8, wherein the antibody or antigen-binding fragment further comprises an antibody constant region sequence having CH2 and CH3 fragments, or wherein the antibody or antigen-binding fragment further comprises an antibody Fc region;the antibody constant region or antibody Fc region is linked to the antibody or antigen binding fragment with or without a linking peptide;alternatively, the antibody constant region or antibody Fc region is from a camelid, mouse, rat, rabbit, sheep or human;alternatively, the antibody constant region or antibody Fc region is from IgG, igA, igM, igD or IgE.
- The nanobody or antigen-binding fragment of any one of claims 1-9, wherein the antibody or antigen-binding fragment is:(1) A chimeric antibody or fragment thereof;(2) A humanized antibody or fragment thereof; or alternatively, the first and second heat exchangers may be,(3) A fully human antibody or fragment thereof;preferably, the antibody or antigen binding fragment is selected from the group consisting of monoclonal antibodies, polyclonal antibodies, natural antibodies, engineered antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies), monovalent antibodies, multivalent antibodies, full length antibodies, antibody fragments, naked antibodies, conjugated antibodies, humanized antibodies, fully human antibodies, fab ', F (ab') 2, fd, fv, scFv, diabodies (diabodies), or single domain antibodies.
- The antibody or antigen-binding fragment of any one of claims 1-10, wherein the antibody or antigen-binding fragment is further conjugated to a therapeutic agent or tracer; preferably, the therapeutic agent is selected from the group consisting of a radioisotope, a chemotherapeutic agent or an immunomodulator, and the tracer is selected from the group consisting of a radiocontrast agent, a paramagnetic ion, a metal, a fluorescent label, a chemiluminescent label, an ultrasound contrast agent or a photosensitizer.
- A multispecific antigen-binding molecule comprising a first antigen-binding moiety comprising the antibody or antigen-binding fragment of any one of claims 1-11, and a second antigen-binding moiety that specifically binds to an antigen other than HSA or to an HSA epitope different from the first antigen-binding moiety;preferably, the additional antigen is selected from the group consisting of CD2, CD3, CD4, CD5, CD7, CD8, CD11a, CD11b, CD18, CD19, CD20, CD23, CD25, CD33, CD38, CD40, CD45, CDW52, CD69, CD70, CD134 (OX 40), ICOS, BCMP7, CD137, CD27L, CDCP1, DPCR1, dudulin2, FLJ20584, FLJ40787, HEK2, KIAA0634, KIAA0659, KIAA1246, KIAA1455, LTBP2, LTK, MAL2, MRP2, MSLN;Preferably, the multispecific antigen-binding molecule is a bispecific, trispecific or tetraspecific antibody.
- A Chimeric Antigen Receptor (CAR) comprising at least an extracellular antigen-binding domain comprising the HSA antibody or antigen-binding fragment of any one of claims 1-11, a transmembrane domain, and an intracellular signaling domain.
- An immune effector cell comprising the chimeric antigen receptor of claim 13 or a nucleic acid fragment encoding the chimeric antigen receptor of claim 13;preferably, the immune effector cell is selected from T cells, NK cells (natural killer cell), NKT cells (natural killer T cell), monocytes, macrophages, dendritic cells or mast cells; the T cells may be selected from inflammatory T cells, cytotoxic T cells, regulatory T cells (tregs) or helper T cells;preferably, the immune effector cell is an allogeneic immune effector cell or an autoimmune cell.
- An isolated nucleic acid molecule encoding the nanobody, antigen-binding fragment, or any combination thereof of any of claims 1-11, the multispecific antigen-binding molecule of claim 12, or the chimeric antigen receptor of claim 13.
- An expression vector comprising the isolated nucleic acid molecule of claim 15.
- An isolated host cell comprising the isolated nucleic acid molecule of claim 15, or the expression vector of claim 16; preferably, the host cell is a eukaryotic cell or a prokaryotic cell; more preferably, the host cell is derived from a mammalian cell, a yeast cell, an insect cell, escherichia coli and/or bacillus subtilis; more preferably, the host cell is selected from the group consisting of an Expi293F cell.
- A method of making the antibody or antigen-binding fragment of any one of claims 1-11 or the multispecific antigen-binding molecule of claim 12, wherein the host cell of claim 17 is cultured under suitable conditions and the antibody or antigen-binding fragment or multispecific antigen-binding molecule is isolated.
- A method of making the immune effector cell of claim 14, comprising introducing into an immune effector cell a nucleic acid fragment encoding the CAR of claim 13, optionally further comprising activating the immune effector cell to express the CAR of claim 13.
- A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1-11, the multispecific antigen-binding molecule of claim 12, the immune effector cell of claim 14, the isolated nucleic acid molecule of claim 15, the expression vector of claim 16, the cell of claim 17, or the product of the method of claim 18 or 19; preferably, the composition further comprises a pharmaceutically acceptable carrier, diluent or adjuvant; preferably, the pharmaceutical composition further comprises an additional anti-tumor agent.
- Use of the antibody or antigen binding fragment of any one of claims 1-11, the multispecific antigen-binding molecule of claim 12, the immune effector cell of claim 14, the isolated nucleic acid molecule of claim 15, the expression vector of claim 16, the cell of claim 17, or the product prepared by the method of claim 18 or 19, or the pharmaceutical composition of claim 20, in the manufacture of a medicament for the prevention and/or treatment of a neoplastic disease or inflammatory disease;preferably, the neoplastic disease is preferably melanoma, clear cell sarcoma, head and neck cancer, bladder cancer, breast cancer, colon cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, kidney cancer, prostate cancer, salivary gland cancer, lung cancer, liver cancer, skin cancer, or brain cancer;preferably, the inflammatory disease is preferably multiple sclerosis, psoriasis, myasthenia gravis, uveitis, systemic lupus erythematosus, or rheumatoid arthritis.
- A method of preventing and/or treating a neoplastic disease or inflammatory disease comprising administering to a patient in need thereof an effective amount of the antibody or antigen binding fragment of any one of claims 1-11, the multispecific antigen-binding molecule of claim 12, the immune effector cell of claim 14, the isolated nucleic acid molecule of claim 15, the expression vector of claim 16 or the product of the method of claim 18 or 19, or the pharmaceutical composition of claim 20;Preferably, the neoplastic disease is preferably melanoma, clear cell sarcoma, head and neck cancer, bladder cancer, breast cancer, colon cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, kidney cancer, prostate cancer, salivary gland cancer, lung cancer, liver cancer, skin cancer, or brain cancer;preferably, the inflammatory disease is preferably multiple sclerosis, psoriasis, myasthenia gravis, uveitis, systemic lupus erythematosus, or rheumatoid arthritis.
- The antibody or antigen binding fragment of any one of claims 1-11, the multispecific antigen-binding molecule of claim 12, the immune effector cell of claim 14, the isolated nucleic acid molecule of claim 15, the expression vector of claim 16, the cell of claim 17, or the product made by the method of claim 18 or 19, or the pharmaceutical composition of claim 20, for use in and/or in the treatment of a neoplastic disease or inflammatory disease;preferably, the neoplastic disease is preferably melanoma, clear cell sarcoma, head and neck cancer, bladder cancer, breast cancer, colon cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, kidney cancer, prostate cancer, salivary gland cancer, lung cancer, liver cancer, skin cancer, or brain cancer;Preferably, the inflammatory disease is preferably multiple sclerosis, psoriasis, myasthenia gravis, uveitis, systemic lupus erythematosus, or rheumatoid arthritis.
- A kit comprising the antibody or antigen-binding fragment thereof of any one of claims 1-11, the multispecific antigen-binding molecule of claim 12, the immune effector cell of claim 14, the isolated nucleic acid molecule of claim 15, the expression vector of claim 16, the cell of claim 17, or the product made by the method of claim 18 or 19, or the pharmaceutical composition of claim 20; optionally, instructions for use are also included.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021103554288 | 2021-04-01 | ||
CN202110355428 | 2021-04-01 | ||
PCT/CN2022/084469 WO2022206900A1 (en) | 2021-04-01 | 2022-03-31 | Anti-human serum albumin (hsa) nanobodies and applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117043184A true CN117043184A (en) | 2023-11-10 |
Family
ID=83457999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280022765.8A Pending CN117043184A (en) | 2021-04-01 | 2022-03-31 | Nanometer antibody for resisting Human Serum Albumin (HSA) and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117043184A (en) |
WO (1) | WO2022206900A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024097639A1 (en) * | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101084014A (en) * | 2004-10-08 | 2007-12-05 | 杜门蒂斯有限公司 | Single domain antibodies against tnfr1 and methods of use therefor |
US20070269422A1 (en) * | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
CN101528778A (en) * | 2006-08-18 | 2009-09-09 | 埃博灵克斯股份有限公司 | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
MX2016014926A (en) * | 2014-05-16 | 2017-05-09 | Ablynx Nv | Improved immunoglobulin variable domains. |
CN107674122A (en) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | A kind of single domain antibody for identifying human serum albumins |
GB201818460D0 (en) * | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
CN111349159A (en) * | 2020-03-17 | 2020-06-30 | 暨南大学 | Anti-human serum albumin nano antibody and application thereof |
-
2022
- 2022-03-31 CN CN202280022765.8A patent/CN117043184A/en active Pending
- 2022-03-31 WO PCT/CN2022/084469 patent/WO2022206900A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2022206900A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN117510635A (en) | C-KIT binding agents | |
CN113603785A (en) | Novel mesothelin antibodies and compositions comprising the same | |
JP2023106392A (en) | Cd3 antigen binding fragment and application thereof | |
WO2022135536A1 (en) | Cd3 humanized antibody and application thereof | |
CN113840835B (en) | Binding molecules | |
WO2022007543A1 (en) | Anti-fgl1 antibody and use thereof | |
WO2021143914A1 (en) | Activated anti-ox40 antibody, production method therefor and application thereof | |
WO2022121928A1 (en) | Anti-egfr nanobody and use thereof | |
TW202237661A (en) | TRISPECIFIC ANTIBODY AGAINST GPRC5DxBCMAxCD3 AND USE THEREOF | |
WO2022121941A1 (en) | Anti-human msln antibody and application thereof | |
WO2023125888A1 (en) | Gprc5d antibody and application thereof | |
WO2022262859A1 (en) | Anti-human msln humanized antibody and use thereof | |
CN115715297A (en) | anti-FLT 3 antibodies and compositions | |
CN117843803A (en) | Novel tandem single domain antibodies and their use in the treatment of disease | |
WO2022127844A1 (en) | Cd5 antibody and use thereof | |
JP2024511642A (en) | Novel TNFR2 binding molecule | |
WO2022206900A1 (en) | Anti-human serum albumin (hsa) nanobodies and applications thereof | |
WO2023098846A1 (en) | Anti-bcma nanobody and use thereof | |
CN114340668A (en) | Heterodimeric antibodies binding to CD38 and CD3 | |
TW202016144A (en) | Compositions including cd3 antigen binding fragments and uses thereof | |
TW202313699A (en) | Novel anti-sirpa antibodies | |
JP2023544140A (en) | Novel anti-claudin 18 antibody | |
WO2024017326A1 (en) | Anti-gprc5d nanobody and use thereof | |
WO2022117032A1 (en) | Anti-cd22 nano antibody and use thereof | |
WO2023186100A1 (en) | Anti-ror1 antibody and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |